If Retatrutide is approved in the future, it is possible that: Private prescribing may become available first NHS eligibility could follow later, subject to NICE guidance However, this will depend entirely on the final licence conditions, safety profile and cost effectiveness decisions
It does, mostly, but several important differences deserve attention
68 HeS.KahlesF.RattikS.NairzM.McAlpineC
These combined mechanisms naturally lead to reduced overall caloric intake, ultimately supporting steady and sustainable weight loss
So at the moment, there are some off label ways to get around that, but I think its going away
Pubblicazione del trial SOUL (NEJM, marzo 2025) la semaglutide orale (Rybelsus) riduce del 14% i MACE in pazienti con diabete tipo 2 e malattia CV/renale